ENSC

SEC source: 0001493152-26-038866 · ownership.xml · nonDerivative · entry 2

GOWER BOB G · CIK 0001136466 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 916,740

SEC source: 0001493152-26-038866 · ownership.xml · derivative · entry 3

GOWER BOB G · CIK 0001136466 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 289,836

Underlying: Common Stock · 254,307 shares

Expires 2028-04-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Amendment and conversion, without payment of additional consideration, of two senior convertible promissory notes, aggregate principal amount $216,000, issued in 2023 into 254,307 shares of common stock as reported in Table 1 above and a warrant to purchase 254,307 shares of common stock as reported in Table II above. In April 2026, the outstanding principal amount, together with accrued and unpaid interest, was $246,169.

SEC source: 0001493152-26-038866 · ownership.xml · nonDerivative · entry 1

GOWER BOB G · CIK 0001136466 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 516,740

F1 · balance_after: The total of securities reported as beneficially owned reflects two reverse stock splits effected by the Issuer subsequent to the last filing on Form 4 by the Reporting Person.

SEC source: 0001493152-23-006786 · ownership.xml · nonDerivative · entry 1

GOWER BOB G · CIK 0001136466 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,222,682

SEC source: 0001493152-23-006553 · ownership.xml · nonDerivative · entry 2

GOWER BOB G · CIK 0001136466 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,132,395

SEC source: 0001493152-23-006553 · ownership.xml · nonDerivative · entry 1

GOWER BOB G · CIK 0001136466 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 862,395

SEC source: 0001493152-23-003343 · ownership.xml · derivative · entry 2

GOWER BOB G · CIK 0001136466 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 716,365

Underlying: Common Stock · 714,286 shares

Expires 2027-12-09

F1 · security: On October 28, 2022, Ensysce Biosciences, Inc. (the "Company"), pursuant to an amendment to the Company's Third Amended and Restated Certificate of Incorporation, effectuated a one-for-twenty reverse stock split of the Company's common stock, par value $0.0001 (the "Common Stock").

F3 · security: On December 9, 2022, Mr. Gower purchased 357,143 warrants to purchase 714,286 shares of Common Stock with an exercise price of $1.40 per share (the "Warrants") in an underwritten offering further described on the Company's Prospectus filed pursuant to Rule 424(b)(4) (File No. 333-268038) filed with the Commission on December 9, 2022. The Warrants are immediately exercisable and may be exercised until five years from the date of issuance.

F3 · price: On December 9, 2022, Mr. Gower purchased 357,143 warrants to purchase 714,286 shares of Common Stock with an exercise price of $1.40 per share (the "Warrants") in an underwritten offering further described on the Company's Prospectus filed pursuant to Rule 424(b)(4) (File No. 333-268038) filed with the Commission on December 9, 2022. The Warrants are immediately exercisable and may be exercised until five years from the date of issuance.

F3 · derivative.exercise_date: On December 9, 2022, Mr. Gower purchased 357,143 warrants to purchase 714,286 shares of Common Stock with an exercise price of $1.40 per share (the "Warrants") in an underwritten offering further described on the Company's Prospectus filed pursuant to Rule 424(b)(4) (File No. 333-268038) filed with the Commission on December 9, 2022. The Warrants are immediately exercisable and may be exercised until five years from the date of issuance.

F3 · balance_after: On December 9, 2022, Mr. Gower purchased 357,143 warrants to purchase 714,286 shares of Common Stock with an exercise price of $1.40 per share (the "Warrants") in an underwritten offering further described on the Company's Prospectus filed pursuant to Rule 424(b)(4) (File No. 333-268038) filed with the Commission on December 9, 2022. The Warrants are immediately exercisable and may be exercised until five years from the date of issuance.

SEC source: 0001493152-23-003343 · ownership.xml · nonDerivative · entry 1

GOWER BOB G · CIK 0001136466 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 753,095

F1 · security: On October 28, 2022, Ensysce Biosciences, Inc. (the "Company"), pursuant to an amendment to the Company's Third Amended and Restated Certificate of Incorporation, effectuated a one-for-twenty reverse stock split of the Company's common stock, par value $0.0001 (the "Common Stock").

F2 · security: On December 9, 2022, Mr. Gower purchased 357,143 shares of Common Stock at a price of $1.40 per share.

F2 · balance_after: On December 9, 2022, Mr. Gower purchased 357,143 shares of Common Stock at a price of $1.40 per share.

SEC source: 0001493152-22-017876 · ownership.xml · derivative · entry 2

GOWER BOB G · CIK 0001136466 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,585

Underlying: Common Stock · 15,000 shares

Expires 2032-06-23

F1 · security: On June 23, 2022, Mr. Gower was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year.

F1 · price: On June 23, 2022, Mr. Gower was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year.

F1 · derivative.exercise_date: On June 23, 2022, Mr. Gower was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year.

SEC source: 0001493152-22-017873 · ownership.xml · derivative · entry 1

Rosebraugh Curtis · CIK 0001869847 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 15,000 shares

Expires 2032-06-23

F1 · security: On June 23, 2022, Mr. Rosebraugh was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year.

F1 · price: On June 23, 2022, Mr. Rosebraugh was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year.

F1 · derivative.exercise_date: On June 23, 2022, Mr. Rosebraugh was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year.

SEC source: 0001493152-22-017877 · ownership.xml · derivative · entry 1

Rauch Lee M. · CIK 0001815345 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 15,000 shares

Expires 2032-06-23

F1 · security: On June 23, 2022, Ms. Rauch was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year.

F1 · price: On June 23, 2022, Ms. Rauch was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year.

F1 · derivative.exercise_date: On June 23, 2022, Ms. Rauch was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year.

SEC source: 0001493152-22-017879 · ownership.xml · derivative · entry 1

Martin Steven Robert · CIK 0001328822 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,850

Underlying: Common Stock · 15,000 shares

Expires 2032-06-23

F1 · security: On June 23, 2022, Mr. Martin was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year.

F1 · price: On June 23, 2022, Mr. Martin was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year.

F1 · derivative.exercise_date: On June 23, 2022, Mr. Martin was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year.

SEC source: 0001493152-22-017881 · ownership.xml · derivative · entry 3

Chang William H · CIK 0001594408 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 15,000 shares

Expires 2032-06-23

F1 · security: On June 23, 2022, Mr. Chang was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year.

F1 · price: On June 23, 2022, Mr. Chang was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year.

F1 · derivative.exercise_date: On June 23, 2022, Mr. Chang was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year.

SEC source: 0001493152-22-017872 · ownership.xml · derivative · entry 1

Benton Andrew · CIK 0001867975 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,850

Underlying: Common Stock · 15,000 shares

Expires 2032-06-23

F1 · security: On June 23, 2022, Mr. Benton was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year.

F1 · price: On June 23, 2022, Mr. Benton was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year.

F1 · derivative.exercise_date: On June 23, 2022, Mr. Benton was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year.

SEC source: 0001493152-22-017869 · ownership.xml · derivative · entry 1

Levin Adam · CIK 0001868308 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 15,000 shares

Expires 2032-06-23

F1 · security: On June 23, 2022, Mr. Levin was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year.

F1 · price: On June 23, 2022, Mr. Levin was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year.

F1 · derivative.exercise_date: On June 23, 2022, Mr. Levin was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year.

SEC source: 0001493152-22-015294 · ownership.xml · nonDerivative · entry 2

Kirkpatrick Lynn · CIK 0001418785 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 381,851

SEC source: 0001493152-22-015294 · ownership.xml · nonDerivative · entry 1

Kirkpatrick Lynn · CIK 0001418785 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 354,851

SEC source: 0001493152-22-005445 · ownership.xml · derivative · entry 1

Humphrey David Carl · CIK 0001708720 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2032-02-17

F1 · security: On February 17, 2022, Mr. Humphrey was granted an option (the "Stock Option") to purchase 80,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter.

F1 · price: On February 17, 2022, Mr. Humphrey was granted an option (the "Stock Option") to purchase 80,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter.

F1 · derivative.exercise_date: On February 17, 2022, Mr. Humphrey was granted an option (the "Stock Option") to purchase 80,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter.

SEC source: 0001493152-22-005440 · ownership.xml · derivative · entry 1

Kirkpatrick Lynn · CIK 0001418785 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2032-02-17

F1 · security: On February 17, 2022, Dr. Kirkpatrick was granted an option (the "Stock Option") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter.

F1 · price: On February 17, 2022, Dr. Kirkpatrick was granted an option (the "Stock Option") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter.

F1 · derivative.exercise_date: On February 17, 2022, Dr. Kirkpatrick was granted an option (the "Stock Option") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter.

SEC source: 0001493152-22-005444 · ownership.xml · derivative · entry 1

Birkett Kevin Geoffrey · CIK 0001867942 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2032-02-17

F1 · security: On February 17, 2022, Mr. Birkett was granted an option (the "Stock Option") to purchase 50,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter.

F1 · price: On February 17, 2022, Mr. Birkett was granted an option (the "Stock Option") to purchase 50,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter.

F1 · derivative.exercise_date: On February 17, 2022, Mr. Birkett was granted an option (the "Stock Option") to purchase 50,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter.

SEC source: 0001493152-22-015294 · ownership.xml · derivative · entry 3

Kirkpatrick Lynn · CIK 0001418785 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,516,939

Underlying: Common Stock · 200,000 shares

Expires 2032-02-17

F1 · security: On February 17, 2022, Dr. Kirkpatrick was granted an option (the "Stock Option") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter. The Form 4 filed February 24, 2022 included this same information for Table II except for the entry under column 9.

F1 · price: On February 17, 2022, Dr. Kirkpatrick was granted an option (the "Stock Option") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter. The Form 4 filed February 24, 2022 included this same information for Table II except for the entry under column 9.

F1 · derivative.exercise_date: On February 17, 2022, Dr. Kirkpatrick was granted an option (the "Stock Option") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with an exercise price of $1.40. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 17, 2022 and the remainder in equal installments monthly for the thirty-six months thereafter. The Form 4 filed February 24, 2022 included this same information for Table II except for the entry under column 9.

SEC source: 0001493152-22-003208 · ownership.xml · derivative · entry 1

GOWER BOB G · CIK 0001136466 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2032-02-04

F1 · security: On February 4, 2022, Mr. Gower was granted an option (the "Stock Option") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022.

F1 · price: On February 4, 2022, Mr. Gower was granted an option (the "Stock Option") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022.

F1 · derivative.exercise_date: On February 4, 2022, Mr. Gower was granted an option (the "Stock Option") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022.

SEC source: 0001493152-22-003210 · ownership.xml · derivative · entry 1

Rosebraugh Curtis · CIK 0001869847 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2032-02-04

F1 · security: On February 4, 2022, Mr. Rosebraugh was granted an option (the "Stock Option") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022.

F1 · price: On February 4, 2022, Mr. Rosebraugh was granted an option (the "Stock Option") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022.

F1 · derivative.exercise_date: On February 4, 2022, Mr. Rosebraugh was granted an option (the "Stock Option") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022.

SEC source: 0001493152-22-003204 · ownership.xml · derivative · entry 1

Humphrey David Carl · CIK 0001708720 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 275,000

Underlying: Common Stock · 275,000 shares

Expires 2032-02-04

F1 · security: On February 4, 2022, Mr. Humphrey was granted an option (the "Stock Option") to purchase 275,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $3.13. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 11, 2021 and the remainder in equal installments monthly for the thirty-six months thereafter.

F1 · price: On February 4, 2022, Mr. Humphrey was granted an option (the "Stock Option") to purchase 275,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $3.13. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 11, 2021 and the remainder in equal installments monthly for the thirty-six months thereafter.

F1 · derivative.exercise_date: On February 4, 2022, Mr. Humphrey was granted an option (the "Stock Option") to purchase 275,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $3.13. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of February 11, 2021 and the remainder in equal installments monthly for the thirty-six months thereafter.

SEC source: 0001493152-22-003216 · ownership.xml · derivative · entry 1

Martin Steven Robert · CIK 0001328822 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2032-02-04

F1 · security: On February 4, 2022, Mr. Martin was granted an option (the "Stock Option") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022.

F1 · price: On February 4, 2022, Mr. Martin was granted an option (the "Stock Option") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022.

F1 · derivative.exercise_date: On February 4, 2022, Mr. Martin was granted an option (the "Stock Option") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022.

SEC source: 0001493152-22-003218 · ownership.xml · derivative · entry 1

Chang William H · CIK 0001594408 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2032-02-04

F1 · security: On February 4, 2022, Mr. Chang was granted an option (the "Stock Option") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022.

F1 · price: On February 4, 2022, Mr. Chang was granted an option (the "Stock Option") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022.

F1 · derivative.exercise_date: On February 4, 2022, Mr. Chang was granted an option (the "Stock Option") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022.

SEC source: 0001493152-22-003220 · ownership.xml · derivative · entry 1

Benton Andrew · CIK 0001867975 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2032-02-04

F1 · security: On February 4, 2022, Mr. Benton was granted an option (the "Stock Option") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022.

F1 · price: On February 4, 2022, Mr. Benton was granted an option (the "Stock Option") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022.

F1 · derivative.exercise_date: On February 4, 2022, Mr. Benton was granted an option (the "Stock Option") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022.

SEC source: 0001493152-22-003213 · ownership.xml · derivative · entry 1

Levin Adam · CIK 0001868308 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2032-02-04

F1 · security: On February 4, 2022, Mr. Levin was granted an option (the "Stock Option") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022.

F1 · price: On February 4, 2022, Mr. Levin was granted an option (the "Stock Option") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022.

F1 · derivative.exercise_date: On February 4, 2022, Mr. Levin was granted an option (the "Stock Option") to purchase 20,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $3.13, under the that certain Ensysce Biosciences, Inc. Amended and Restated 2021 Omnibus Incentive Plan. The Stock Option is scheduled to vest on the date of the Company's annual stockholder meeting in 2022.

SEC source: 0001493152-22-003206 · ownership.xml · derivative · entry 1

Pestano Linda · CIK 0001892759 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2032-02-04

F1 · security: On February 4, 2022, Ms. Pestano was granted an option (the "Stock Option") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $2.48. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of October 15, 2021 and the remainder in equal installments monthly for the thirty-six months thereafter.

F1 · price: On February 4, 2022, Ms. Pestano was granted an option (the "Stock Option") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $2.48. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of October 15, 2021 and the remainder in equal installments monthly for the thirty-six months thereafter.

F1 · derivative.exercise_date: On February 4, 2022, Ms. Pestano was granted an option (the "Stock Option") to purchase 200,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.01 per share, with an exercise price of $2.48. The Stock Option is scheduled to vest over four years with 1/4 vesting upon the one year anniversary of October 15, 2021 and the remainder in equal installments monthly for the thirty-six months thereafter.

SEC source: 0001493152-21-015905 · ownership.xml · derivative · entry 4

WEIL A LORNE · CIK 0000921873 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Hydra Management LLC

Disclosed balance after: 137,895

Underlying: Common Stock · 250,000 shares

Expires 2026-06-30

F4 · security: Reflects warrants surrendered to the Issuer in connection with the Issuer's business combination pursuant to a warrant surrender agreement, for no consideration.

F4 · kind: Reflects warrants surrendered to the Issuer in connection with the Issuer's business combination pursuant to a warrant surrender agreement, for no consideration.

F2 · ownership.nature: Mr. Weil is the managing member of Hydra LAC LLC and the sole member of Hydra Management LLC and disclaims beneficial ownership with respect to the securities except to the extent of his pecuniary interest therein.

SEC source: 0001493152-21-015905 · ownership.xml · derivative · entry 3

WEIL A LORNE · CIK 0000921873 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Hydra Management LLC

Disclosed balance after: 387,895

Underlying: Common Stock · 387,895 shares

Expires 2026-06-30

F3 · security: Reflects warrants acquired at a price of $1.00 per warrant upon the conversion of promissory notes of the Issuer held by Hydra Management LLC reflecting amounts loaned to the Issuer pursuant to the Issuer's expense advancement agreement, which were convertible into warrants at the holder's option. The warrants are on the same terms as the warrants described in note (1) above.

F3 · kind: Reflects warrants acquired at a price of $1.00 per warrant upon the conversion of promissory notes of the Issuer held by Hydra Management LLC reflecting amounts loaned to the Issuer pursuant to the Issuer's expense advancement agreement, which were convertible into warrants at the holder's option. The warrants are on the same terms as the warrants described in note (1) above.

F2 · ownership.nature: Mr. Weil is the managing member of Hydra LAC LLC and the sole member of Hydra Management LLC and disclaims beneficial ownership with respect to the securities except to the extent of his pecuniary interest therein.

SEC source: 0001493152-21-015905 · ownership.xml · derivative · entry 2

WEIL A LORNE · CIK 0000921873 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Hydra LAC LLC

Disclosed balance after: 1,000,000

Underlying: Common Stock · 1,000,000 shares

Expires 2026-06-30

F1 · security: Reflects warrants of Ensysce Biosciences, Inc., formerly known as Leisure Acquisition Corp. (the "Issuer"), which were acquired from the Issuer at a price of $1.00 per warrant (730,110 warrants by Mr. Weil at a cost of $730,110 and 1,000,000 warrants by Hydra LAC LLC (an entity affiliated with Mr. Weil) at a cost of $1,000,000) in a private placement that closed simultaneously with the closing of the Issuer's initial public offering which were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination which occurred on June 30, 2021. Mr. Weil served as the Issuer's Executive Chairman until the closing of the business combination.

F1 · kind: Reflects warrants of Ensysce Biosciences, Inc., formerly known as Leisure Acquisition Corp. (the "Issuer"), which were acquired from the Issuer at a price of $1.00 per warrant (730,110 warrants by Mr. Weil at a cost of $730,110 and 1,000,000 warrants by Hydra LAC LLC (an entity affiliated with Mr. Weil) at a cost of $1,000,000) in a private placement that closed simultaneously with the closing of the Issuer's initial public offering which were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination which occurred on June 30, 2021. Mr. Weil served as the Issuer's Executive Chairman until the closing of the business combination.

F2 · ownership.nature: Mr. Weil is the managing member of Hydra LAC LLC and the sole member of Hydra Management LLC and disclaims beneficial ownership with respect to the securities except to the extent of his pecuniary interest therein.

SEC source: 0001493152-21-015905 · ownership.xml · derivative · entry 1

WEIL A LORNE · CIK 0000921873 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 730,110

Underlying: Common Stock · 730,110 shares

Expires 2026-06-30

F1 · security: Reflects warrants of Ensysce Biosciences, Inc., formerly known as Leisure Acquisition Corp. (the "Issuer"), which were acquired from the Issuer at a price of $1.00 per warrant (730,110 warrants by Mr. Weil at a cost of $730,110 and 1,000,000 warrants by Hydra LAC LLC (an entity affiliated with Mr. Weil) at a cost of $1,000,000) in a private placement that closed simultaneously with the closing of the Issuer's initial public offering which were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination which occurred on June 30, 2021. Mr. Weil served as the Issuer's Executive Chairman until the closing of the business combination.

F1 · kind: Reflects warrants of Ensysce Biosciences, Inc., formerly known as Leisure Acquisition Corp. (the "Issuer"), which were acquired from the Issuer at a price of $1.00 per warrant (730,110 warrants by Mr. Weil at a cost of $730,110 and 1,000,000 warrants by Hydra LAC LLC (an entity affiliated with Mr. Weil) at a cost of $1,000,000) in a private placement that closed simultaneously with the closing of the Issuer's initial public offering which were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination which occurred on June 30, 2021. Mr. Weil served as the Issuer's Executive Chairman until the closing of the business combination.

SEC source: 0001493152-21-015901 · ownership.xml · derivative · entry 1

Carrera Eric · CIK 0001657726 · Former officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2026-06-30

F1 · security: Reflects warrants of Ensysce Biosciences, Inc., formerly known as Leisure Acquisition Corp. (the "Issuer"), which were acquired from the Issuer at a price of $1.00 per warrant in a private placement that closed simultaneously with the closing of the Issuer's initial public offering which were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination which occurred on June 30, 2021. Mr. Carrera served as the Issuer's Senior Vice President of Finance and Business Development until the closing of the business combination.

F1 · kind: Reflects warrants of Ensysce Biosciences, Inc., formerly known as Leisure Acquisition Corp. (the "Issuer"), which were acquired from the Issuer at a price of $1.00 per warrant in a private placement that closed simultaneously with the closing of the Issuer's initial public offering which were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination which occurred on June 30, 2021. Mr. Carrera served as the Issuer's Senior Vice President of Finance and Business Development until the closing of the business combination.

SEC source: 0001493152-21-015899 · ownership.xml · derivative · entry 3

Silvers Daniel B. · CIK 0001468195 · 10% owner

Matthews Lane Capital Partners LLC · CIK 0001722952 · 10% owner

MLCP GLL Funding LLC · CIK 0001722935 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · MLCP GLL Funding LLC

Disclosed balance after: 1,754,497

Underlying: Common Stock · 250,000 shares

Expires 2026-06-30

F4 · security: Reflects warrants surrendered to the Issuer in connection with the Issuer's business combination pursuant to a warrant surrender agreement, for no consideration.

F4 · kind: Reflects warrants surrendered to the Issuer in connection with the Issuer's business combination pursuant to a warrant surrender agreement, for no consideration.

F2 · ownership.nature: Matthews Lane Capital Partners LLC, a sponsor of the Issuer, is the manager of MLCP GLL Funding LLC, the record holder of the warrants. Mr. Silvers is the managing member of Matthews Lane Capital Partners LLC and disclaims beneficial ownership with respect to the securities except to the extent of his pecuniary interest therein.

SEC source: 0001493152-21-015899 · ownership.xml · derivative · entry 2

Silvers Daniel B. · CIK 0001468195 · 10% owner

Matthews Lane Capital Partners LLC · CIK 0001722952 · 10% owner

MLCP GLL Funding LLC · CIK 0001722935 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · MLCP GLL Funding LLC

Disclosed balance after: 2,004,497

Underlying: Common Stock · 367,107 shares

Expires 2026-06-30

F3 · security: Reflects warrants acquired at a price of $1.00 per warrant upon the conversion of promissory notes of the Issuer reflecting amounts loaned to the Issuer pursuant to the Issuer's expense advancement agreement, which were convertible into warrants at the holder's option. The warrants are on the same terms as the warrants described in note (1) above.

F3 · kind: Reflects warrants acquired at a price of $1.00 per warrant upon the conversion of promissory notes of the Issuer reflecting amounts loaned to the Issuer pursuant to the Issuer's expense advancement agreement, which were convertible into warrants at the holder's option. The warrants are on the same terms as the warrants described in note (1) above.

F2 · ownership.nature: Matthews Lane Capital Partners LLC, a sponsor of the Issuer, is the manager of MLCP GLL Funding LLC, the record holder of the warrants. Mr. Silvers is the managing member of Matthews Lane Capital Partners LLC and disclaims beneficial ownership with respect to the securities except to the extent of his pecuniary interest therein.

SEC source: 0001493152-21-015899 · ownership.xml · derivative · entry 1

Silvers Daniel B. · CIK 0001468195 · 10% owner

Matthews Lane Capital Partners LLC · CIK 0001722952 · 10% owner

MLCP GLL Funding LLC · CIK 0001722935 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · MLCP GLL Funding LLC

Disclosed balance after: 1,637,390

Underlying: Common Stock · 1,637,390 shares

Expires 2026-06-30

F1 · security: Reflects warrants of Ensysce Biosciences, Inc., formerly known as Leisure Acquisition Corp. (the "Issuer"), which were acquired from the Issuer at a price of $1.00 per warrant in a private placement that closed simultaneously with the closing of the Issuer's initial public offering which were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination which occurred on June 30, 2021. Mr. Silvers served as the Issuer's Chief Executive Officer and Director until the closing of the business combination.

F1 · kind: Reflects warrants of Ensysce Biosciences, Inc., formerly known as Leisure Acquisition Corp. (the "Issuer"), which were acquired from the Issuer at a price of $1.00 per warrant in a private placement that closed simultaneously with the closing of the Issuer's initial public offering which were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination which occurred on June 30, 2021. Mr. Silvers served as the Issuer's Chief Executive Officer and Director until the closing of the business combination.

F2 · ownership.nature: Matthews Lane Capital Partners LLC, a sponsor of the Issuer, is the manager of MLCP GLL Funding LLC, the record holder of the warrants. Mr. Silvers is the managing member of Matthews Lane Capital Partners LLC and disclaims beneficial ownership with respect to the securities except to the extent of his pecuniary interest therein.

SEC source: 0001493152-21-015903 · ownership.xml · derivative · entry 1

Peng George · CIK 0001651293 · Former officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2026-06-30

F1 · security: Reflects warrants of Ensysce Biosciences, Inc., formerly known as Leisure Acquisition Corp. (the "Issuer"), which were acquired from the Issuer at a price of $1.00 per warrant in a private placement that closed simultaneously with the closing of the Issuer's initial public offering which were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination which occurred on June 30, 2021. Mr. Peng served as the Issuer's Chief Financial Officer until the closing of the business combination.

F1 · kind: Reflects warrants of Ensysce Biosciences, Inc., formerly known as Leisure Acquisition Corp. (the "Issuer"), which were acquired from the Issuer at a price of $1.00 per warrant in a private placement that closed simultaneously with the closing of the Issuer's initial public offering which were later exchanged for warrants having the same terms, except that they are non-transferable other than to permitted transferees. Pursuant to the terms of the issuance, such warrants were not eligible to become exercisable unless the Issuer consummated its initial business combination which occurred on June 30, 2021. Mr. Peng served as the Issuer's Chief Financial Officer until the closing of the business combination.

SEC source: 0001192482-21-000620 · edgar.xml · derivative · entry 2

GOWER BOB G · CIK 0001136466 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,585

Underlying: Common Stock · 6,585 shares

Expires 2029-03-14

F2 · price: Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement.

SEC source: 0001192482-21-000620 · edgar.xml · nonDerivative · entry 1

GOWER BOB G · CIK 0001136466 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,919,026

F1 · price: On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the "Merger Agreement") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the "Issuer"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and Ensysce Biosciences, Inc., a Delaware corporation ("Ensysce"), Merger Sub merged with and into Ensysce (the "Merger"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of Ensysce common stock was automatically converted into the right to receive a pro rata portion of 17,334,518 shares of the Issuer's common stock.

SEC source: 0001192482-21-000614 · edgar.xml · derivative · entry 5

Wright Richard Chester · CIK 0001869634 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 987,750

Underlying: Common Stock · 987,750 shares

Expires 2029-02-28

F1 · price: On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the "Merger Agreement") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the "Issuer"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and Ensysce Biosciences, Inc., a Delaware corporation ("Ensysce"), Merger Sub merged with and into Ensysce (the "Merger"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement.

F1 · derivative.exercise_date: On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the "Merger Agreement") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the "Issuer"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and Ensysce Biosciences, Inc., a Delaware corporation ("Ensysce"), Merger Sub merged with and into Ensysce (the "Merger"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement.

SEC source: 0001192482-21-000614 · edgar.xml · derivative · entry 4

Wright Richard Chester · CIK 0001869634 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,755

Underlying: Common Stock · 19,755 shares

Expires 2028-10-01

F1 · price: On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the "Merger Agreement") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the "Issuer"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and Ensysce Biosciences, Inc., a Delaware corporation ("Ensysce"), Merger Sub merged with and into Ensysce (the "Merger"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement.

F1 · derivative.exercise_date: On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the "Merger Agreement") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the "Issuer"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and Ensysce Biosciences, Inc., a Delaware corporation ("Ensysce"), Merger Sub merged with and into Ensysce (the "Merger"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement.

SEC source: 0001192482-21-000614 · edgar.xml · derivative · entry 3

Wright Richard Chester · CIK 0001869634 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 263,400

Underlying: Common Stock · 263,400 shares

Expires 2027-07-01

F1 · price: On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the "Merger Agreement") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the "Issuer"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and Ensysce Biosciences, Inc., a Delaware corporation ("Ensysce"), Merger Sub merged with and into Ensysce (the "Merger"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement.

F1 · derivative.exercise_date: On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the "Merger Agreement") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the "Issuer"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and Ensysce Biosciences, Inc., a Delaware corporation ("Ensysce"), Merger Sub merged with and into Ensysce (the "Merger"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement.

SEC source: 0001192482-21-000614 · edgar.xml · derivative · entry 2

Wright Richard Chester · CIK 0001869634 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,850

Underlying: Common Stock · 65,850 shares

Expires 2026-11-01

F1 · price: On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the "Merger Agreement") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the "Issuer"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and Ensysce Biosciences, Inc., a Delaware corporation ("Ensysce"), Merger Sub merged with and into Ensysce (the "Merger"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement.

F1 · derivative.exercise_date: On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the "Merger Agreement") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the "Issuer"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and Ensysce Biosciences, Inc., a Delaware corporation ("Ensysce"), Merger Sub merged with and into Ensysce (the "Merger"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement.

SEC source: 0001192482-21-000614 · edgar.xml · derivative · entry 1

Wright Richard Chester · CIK 0001869634 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,975

Underlying: Common Stock · 49,975 shares

Expires 2023-12-21

F1 · price: On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the "Merger Agreement") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the "Issuer"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and Ensysce Biosciences, Inc., a Delaware corporation ("Ensysce"), Merger Sub merged with and into Ensysce (the "Merger"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement.

F1 · derivative.exercise_date: On June 30, 2021, pursuant to that certain Agreement and Plan of Merger dated January 31, 2021 (the "Merger Agreement") among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the "Issuer"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and Ensysce Biosciences, Inc., a Delaware corporation ("Ensysce"), Merger Sub merged with and into Ensysce (the "Merger"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement.

SEC source: 0001493152-21-016123 · ownership.xml · nonDerivative · entry 1

Humphrey David Carl · CIK 0001708720 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

F1 · shares: On June 30, 2021, pursuant to that certain Agreement and Plan of Merger, dated January 31, 2021, among Ensysce Biosciences, Inc. (f/k/a Leisure Acquisition Corp.) (the "Issuer"), EB Merger Sub, Inc., a Delaware corporation and wholly-owned, direct subsidiary of the Issuer ("Merger Sub"), and Ensysce Biosciences, Inc., a Delaware corporation ("Ensysce"), Merger Sub merged with and into Ensysce (the "Merger"), with Ensysce surviving as a wholly owned subsidiary of the Issuer. Upon completion of the Merger, the Reporting Person received a grant of 50,000 restricted stock units, which, subject generally to the Reporting Person's continued employment through each such date would vest as to 20,000 restricted stock units on December 15, 2021, an additional 15,000 restricted stock units on December 15, 2022, and an additional 15,000 restricted stock units on December 15, 2023.

SEC source: 0001192482-21-000618 · edgar.xml · derivative · entry 8

Kirkpatrick Lynn · CIK 0001418785 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,585

Underlying: Common Stock · 6,585 shares

Expires 2029-03-14

F2 · price: Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement.

SEC source: 0001192482-21-000618 · edgar.xml · derivative · entry 7

Kirkpatrick Lynn · CIK 0001418785 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 658,500

Underlying: Common Stock · 658,500 shares

Expires 2029-02-28

F2 · price: Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement.

SEC source: 0001192482-21-000618 · edgar.xml · derivative · entry 6

Kirkpatrick Lynn · CIK 0001418785 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 817,560

Underlying: Common Stock · 817,560 shares

Expires 2028-02-05

F2 · price: Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement.

SEC source: 0001192482-21-000618 · edgar.xml · derivative · entry 5

Kirkpatrick Lynn · CIK 0001418785 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 460,950

Underlying: Common Stock · 460,950 shares

Expires 2027-01-04

F2 · price: Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each option and warrant of Ensysce that was outstanding and unexercised immediately prior to the Effective Time was assumed by the Issuer (each, a "Derivative Security") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement.